TechCrunch

Aloe Blacc’s Fame Means Nothing in Biotech (and That’s the Point) | Equity Podcast

The Equity Tech Crunch podcast features Grammy‑nominated singer‑songwriter Aloe Blacc, who has transitioned from music to biotech entrepreneurship. He co‑founded Major Inc. and its spin‑off Pepto ID to develop novel cancer therapies, focusing on pancreatic cancer, a disease with a 90 % mortality rate and no approved drugs. Blacc explains that his venture relies on a unique platform created by Dr. Gika Urugamasurya, which can design, synthesize, and screen hundreds of thousands of molecular candidates in silico and in vitro. The approach has already yielded ten patents and promises to shave years and millions of dollars off traditional drug‑development timelines. Funding is currently bootstrapped with Blacc’s own capital, supplemented by non‑dilutive government grants, while a future VC round is planned once peer‑reviewed data are published. He highlights how the COVID‑19 pandemic accelerated regulatory pathways for technologies like mRNA, underscoring the difficulty of securing investment in biotech without clear scientific validation. Blacc also contrasts biotech’s structured FDA pipeline with the music industry’s vague AI‑generated content rules, noting that while AI can replicate artistic styles, human storytelling and brand narrative remain decisive for audience engagement. The conversation illustrates a broader trend of creators leveraging their platforms to address high‑impact problems, while also exposing the financial and regulatory hurdles that differentiate biotech from other tech sectors. For investors and artists alike, the episode underscores the importance of scientific rigor, strategic funding, and the evolving role of AI across disparate industries.